COLOPLAST SP.ADR 1/10 DK1 (CBH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, COLOPLAST SP.ADR 1/10 DK1 (CBH) has a cash flow conversion efficiency ratio of 0.162x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€2.23 Billion ≈ $2.61 Billion USD) by net assets (€13.80 Billion ≈ $16.14 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CBH equity financing ratio to measure how much of total assets are equity-financed.
COLOPLAST SP.ADR 1/10 DK1 - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how COLOPLAST SP.ADR 1/10 DK1's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of COLOPLAST SP.ADR 1/10 DK1 to evaluate the quality of earnings relative to operating cash generation.
COLOPLAST SP.ADR 1/10 DK1 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of COLOPLAST SP.ADR 1/10 DK1 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Samsung Heavy Industries
KO:010140
|
-0.018x |
|
LLOYDS METALS AND ENERGY LTD.
NSE:LLOYDSME
|
-0.114x |
|
Smith & Nephew SNATS Inc
NYSE:SNN
|
0.168x |
|
Cipla Limited
NSE:CIPLA
|
0.041x |
|
SK Telecom Co Ltd
KO:017670
|
0.085x |
|
Zhejiang Satellite Petrochemical Co Ltd
SHE:002648
|
0.092x |
|
GRAB HOLDINGS LTD CL.A
F:A6I
|
0.010x |
|
Guardant Health Inc
NASDAQ:GH
|
0.362x |
Annual Cash Flow Conversion Efficiency for COLOPLAST SP.ADR 1/10 DK1 (2021–2024)
The table below shows the annual cash flow conversion efficiency of COLOPLAST SP.ADR 1/10 DK1 from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see CBH company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | €17.94 Billion ≈ $20.98 Billion |
€2.77 Billion ≈ $3.23 Billion |
0.154x | -36.89% |
| 2023-09-30 | €17.30 Billion ≈ $20.22 Billion |
€4.23 Billion ≈ $4.94 Billion |
0.244x | -60.27% |
| 2022-09-30 | €8.29 Billion ≈ $9.69 Billion |
€5.10 Billion ≈ $5.96 Billion |
0.615x | -5.05% |
| 2021-09-30 | €8.17 Billion ≈ $9.55 Billion |
€5.29 Billion ≈ $6.18 Billion |
0.648x | -- |
About COLOPLAST SP.ADR 1/10 DK1
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, wh… Read more